pethidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
analgesics, pethidine derivatives and other synthetic small molecule miu-opioid receptor agonists 1690 57-42-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • meperidine
  • pethidine
  • isonipecaine
  • meperidol
  • pethanol
  • pethidin
  • meperidine hydrochloride
  • pethidine hydrochloride
  • meperidine HCl
  • pethidine HCl
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
  • Molecular weight: 247.34
  • Formula: C15H21NO2
  • CLOGP: 2.23
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 29.54
  • ALOGS: -2.35
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P
0.40 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 3.22 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 13 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 60.65 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 52 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.42 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.90 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.224 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.692 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 25.410 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 28.576 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 82.120 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 71.670 % High 1
herg hERG pIC50 4.738 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 8.128 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 16.788 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 80.970 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPKAPK2,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1 42
kinase-selectivity-class AXL,EIF2AK3,EPHB4,GRK2,PDK4 5
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.984 High 1
mh-clint Mouse hepatocyte intrinsic clearance 93.972 High 1
mppb Mouse plasma protein binding (% unbound) 77.930 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.148 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 82.050 % High 1
rh-clint Rat hepatocyte intrinsic clearance 63.533 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 89.490 % High 1
rppb Rat plasma protein binding (% unbound) 72.910 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 891.251 uM High 1

Approvals:

DateAgencyCompanyOrphan
Nov. 10, 1942 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 4123.93 15.72 2200 24616 461409 90140222
Food allergy 737.43 15.72 279 26537 25199 90576432
Immunodeficiency 610.60 15.72 284 26532 42950 90558681
Temperature regulation disorder 549.36 15.72 194 26622 14385 90587246
Upper respiratory tract infection 528.53 15.72 377 26439 127941 90473690
Foetal death 493.35 15.72 197 26619 20526 90581105
Rash erythematous 421.39 15.72 254 26562 64850 90536781
Contrast media allergy 404.01 15.72 107 26709 2974 90598657
Hyperhidrosis 380.42 15.72 318 26498 135987 90465644
Prescribed overdose 376.97 15.72 276 26540 97349 90504282
Intentional product misuse 374.95 15.72 266 26550 89338 90512293
Psoriasis 370.15 15.72 324 26492 147430 90454201
International normalised ratio fluctuation 351.77 15.72 96 26720 2997 90598634
Exposure during pregnancy 328.86 15.72 378 26438 238032 90363599
Drug intolerance 323.72 15.72 518 26298 447073 90154558
Thrombocytopenia 306.59 15.72 342 26474 208383 90393248
Overdose 285.74 15.72 289 26527 157420 90444211
Bloody discharge 279.67 15.72 75 26741 2188 90599443
Coeliac disease 262.85 15.72 164 26652 44446 90557185
Fluid retention 248.61 15.72 207 26609 87884 90513747
Myoglobin urine present 225.77 15.72 51 26765 711 90600920
Lyme disease 220.57 15.72 72 26744 4190 90597441
Hypertension 219.33 15.72 443 26373 457089 90144542
Rheumatoid arthritis 214.36 15.72 384 26432 362230 90239401
Serotonin syndrome 202.52 15.72 131 26685 37756 90563875
Infusion related reaction 199.00 15.72 403 26413 416377 90185254
Treatment failure 195.30 15.72 334 26482 303594 90298037
Obliterative bronchiolitis 178.99 15.72 55 26761 2626 90599005
Asthma 174.10 15.72 280 26536 241880 90359751
Joint swelling 142.35 15.72 397 26419 502903 90098728
Product use issue 142.04 15.72 306 26510 329613 90272018
Amylase increased 130.22 15.72 56 26760 7016 90594615
Hypersensitivity 122.95 15.72 353 26463 454324 90147307
Infection 117.77 15.72 301 26515 361793 90239838
Bursitis 113.89 15.72 166 26650 131488 90470143
Toxic encephalopathy 109.94 15.72 53 26763 8646 90592985
Rash 106.42 15.72 491 26325 795609 89806022
Hepatic enzyme increased 101.25 15.72 284 26532 360452 90241179
Decreased immune responsiveness 100.68 15.72 50 26766 8698 90592933
Condition aggravated 91.74 15.72 31 26785 595514 90006117
Alopecia 86.96 15.72 20 26796 495051 90106580
Troponin increased 86.27 15.72 52 26764 13229 90588402
Pyrexia 84.91 15.72 403 26413 660082 89941549
Back pain 83.41 15.72 244 26572 316931 90284700
Glossodynia 82.00 15.72 3 26813 321776 90279855
Herpes zoster 79.88 15.72 118 26698 94526 90507105
Pain 76.73 15.72 530 26286 995811 89605820
Iron deficiency 73.96 15.72 42 26774 9570 90592061
Erythema 73.81 15.72 190 26626 229056 90372575
Blood potassium increased 67.43 15.72 53 26763 20696 90580935
Constipation 67.36 15.72 209 26607 280186 90321445
Hand deformity 63.12 15.72 7 26809 296355 90305276
Blood lactate dehydrogenase increased 61.04 15.72 55 26761 25877 90575754
Synovitis 58.50 15.72 13 26803 329739 90271892
Diarrhoea 58.44 15.72 119 26697 939071 89662560
Pemphigus 57.76 15.72 13 26803 326851 90274780
Wound 55.69 15.72 11 26805 302969 90298662
Weight increased 54.24 15.72 28 26788 417899 90183732
General physical health deterioration 53.72 15.72 19 26797 355096 90246535
Systemic lupus erythematosus 53.67 15.72 20 26796 361876 90239755
Pericarditis 51.37 15.72 9 26807 270142 90331489
Contraindicated product administered 50.57 15.72 208 26608 319931 90281700
Secretion discharge 50.35 15.72 40 26776 15856 90585775
Peripheral swelling 50.25 15.72 30 26786 413076 90188555
Blister 49.58 15.72 8 26808 254990 90346641
Blood creatine phosphokinase increased 48.50 15.72 55 26761 33968 90567663
Bronchitis chronic 48.41 15.72 25 26791 4718 90596913
Nasopharyngitis 47.53 15.72 31 26785 407073 90194558
Product use in unapproved indication 47.52 15.72 20 26796 336216 90265415
Vomiting 47.36 15.72 396 26420 787897 89813734
Anti-cyclic citrullinated peptide antibody positive 44.68 15.72 8 26808 236425 90365206
Discomfort 44.45 15.72 13 26803 274322 90327309
Impaired healing 44.10 15.72 8 26808 234191 90367440
Nausea 43.00 15.72 509 26307 1109807 89491824
Duodenal ulcer perforation 42.89 15.72 7 26809 221281 90380350
Platelet count increased 42.83 15.72 41 26775 20818 90580813
Abdominal discomfort 42.69 15.72 47 26769 477281 90124350
Retching 41.90 15.72 39 26777 19120 90582511
Arthropathy 41.26 15.72 29 26787 366213 90235418
Asthenia 41.02 15.72 59 26757 533692 90067939
Stomatitis 41.02 15.72 15 26801 274683 90326948
Staphylococcal infection 40.28 15.72 60 26756 48379 90553252
Arthralgia 40.07 15.72 109 26707 778413 89823218
Weight decreased 39.08 15.72 33 26783 379877 90221754
Pneumonia 38.63 15.72 82 26734 637977 89963654
Dyspnoea 38.48 15.72 133 26683 880822 89720809
Hallucination 37.70 15.72 69 26747 65890 90535741
Blood cholesterol increased 37.28 15.72 8 26808 208004 90393627
Sinusitis 36.28 15.72 29 26787 343059 90258572
Headache 36.23 15.72 402 26414 862344 89739287
Product dose omission issue 35.71 15.72 21 26795 291666 90309965
Wheezing 35.54 15.72 13 26803 238067 90363564
Mobility decreased 35.28 15.72 15 26801 250719 90350912
Rheumatic fever 34.20 15.72 3 26813 153118 90448513
Contusion 33.82 15.72 16 26800 251200 90350431
Death 33.57 15.72 52 26764 456499 90145132
Respiratory arrest 33.21 15.72 45 26771 33266 90568365
Memory impairment 32.58 15.72 9 26807 197235 90404396
Type 2 diabetes mellitus 32.24 15.72 10 26806 203234 90398397
Confusional state 31.35 15.72 41 26775 386164 90215467
Therapeutic product effect decreased 31.22 15.72 22 26794 277549 90324082
Lung disorder 30.76 15.72 4 26812 149879 90451752
Ill-defined disorder 29.50 15.72 9 26807 184882 90416749
Joint range of motion decreased 29.38 15.72 3 26813 135640 90465991
Psoriatic arthropathy 28.56 15.72 16 26800 228319 90373312
Irritable bowel syndrome 28.25 15.72 13 26803 207435 90394196
Acute kidney injury 28.12 15.72 32 26784 320355 90281276
Lower respiratory tract infection 28.01 15.72 20 26796 250639 90350992
Swelling 27.79 15.72 51 26765 419007 90182624
Intentional product use issue 27.42 15.72 15 26801 216877 90384754
Injection site pain 26.75 15.72 9 26807 173690 90427941
Muscular weakness 26.55 15.72 14 26802 206652 90394979
Respiratory alkalosis 26.34 15.72 15 26801 3433 90598198
Neonatal seizure 26.27 15.72 9 26807 608 90601023
Rheumatoid factor positive 26.25 15.72 9 26807 171641 90429990
Disease progression 26.14 15.72 7 26809 156608 90445023
Liver injury 25.98 15.72 9 26807 170558 90431073
Decreased appetite 25.70 15.72 45 26771 376495 90225136
Helicobacter infection 25.48 15.72 18 26798 226832 90374799
C-reactive protein increased 25.27 15.72 11 26805 181378 90420253
Neutropenia 25.06 15.72 18 26798 224886 90376745
Hospitalisation 24.93 15.72 4 26812 128096 90473535
Anaphylactic reaction 23.58 15.72 68 26748 87456 90514175
Limb mass 23.39 15.72 14 26802 3514 90598117
Sleep disorder 23.19 15.72 15 26801 198015 90403616
Liver disorder 23.13 15.72 4 26812 121265 90480366
Extremity contracture 23.02 15.72 10 26806 1283 90600348
C-reactive protein abnormal 22.62 15.72 5 26811 127424 90474207
Anaemia 22.45 15.72 44 26772 352758 90248873
Oedema 22.35 15.72 16 26800 200279 90401352
Muscle spasms 22.27 15.72 25 26791 251858 90349773
Adverse event 22.11 15.72 4 26812 117414 90484217
Paraesthesia 21.96 15.72 25 26791 250301 90351330
Neonatal respiratory depression 21.89 15.72 6 26810 190 90601441
Cardiac aneurysm 21.76 15.72 9 26807 1023 90600608
Moaning 21.67 15.72 9 26807 1034 90600597
Osteoarthritis 21.37 15.72 16 26800 195714 90405917
Pancreatic carcinoma recurrent 21.09 15.72 5 26811 87 90601544
Arteriospasm coronary 21.09 15.72 15 26801 5035 90596596
Pulse absent 20.83 15.72 16 26800 6039 90595592
Therapeutic product effect incomplete 20.35 15.72 112 26704 193784 90407847
Gastrointestinal disorder 20.05 15.72 28 26788 256659 90344972
Skin reaction 19.93 15.72 26 26790 18527 90583104
Musculoskeletal stiffness 19.72 15.72 36 26780 296496 90305135
Therapy non-responder 19.50 15.72 8 26808 136696 90464935
Drug level below therapeutic 19.21 15.72 15 26801 5799 90595832
Fall 18.84 15.72 76 26740 481734 90119897
Nervous system disorder 18.31 15.72 27 26789 21566 90580065
Dry mouth 17.70 15.72 17 26799 184042 90417589
Fibromyalgia 17.66 15.72 21 26795 206248 90395383
Gait inability 17.27 15.72 11 26805 146445 90455186
Obesity 17.07 15.72 5 26811 105502 90496129
COVID-19 16.93 15.72 15 26801 168828 90432803
Gastrooesophageal reflux disease 16.42 15.72 15 26801 166322 90435309
Breath sounds absent 16.38 15.72 5 26811 233 90601398
Night sweats 16.13 15.72 9 26807 128757 90472874
Pulmonary fibrosis 15.81 15.72 6 26810 107497 90494134
Lower limb fracture 15.78 15.72 3 26813 85010 90516621

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nightmare 525.95 17.52 191 7714 24821 42588609
Drug hypersensitivity 507.35 17.52 281 7624 99108 42514322
Sedation 503.43 17.52 195 7710 30280 42583150
Nephrolithiasis 372.07 17.52 166 7739 36664 42576766
Hyperhidrosis 337.19 17.52 209 7696 90303 42523127
Nausea 143.98 17.52 260 7645 396539 42216891
Product used for unknown indication 112.48 17.52 29 7876 1172 42612258
Product use in unapproved indication 105.29 17.52 149 7756 184307 42429123
Serotonin syndrome 94.09 17.52 59 7846 25786 42587644
Chills 58.00 17.52 79 7826 93987 42519443
Drug ineffective 47.63 17.52 236 7669 629961 41983469
Administration related reaction 41.36 17.52 9 7896 172 42613258
Mucosal atrophy 29.67 17.52 6 7899 79 42613351
Oesophageal mucosa erythema 27.33 17.52 5 7900 37 42613393
Facial wasting 27.17 17.52 6 7899 123 42613307
Off label use 26.99 17.52 206 7699 638129 41975301
Respiratory arrest 25.75 17.52 29 7876 28395 42585035
Drug dependence 25.20 17.52 29 7876 29065 42584365
Motor developmental delay 24.98 17.52 8 7897 703 42612727
Drug abuser 23.56 17.52 12 7893 3519 42609911
Carditis 23.37 17.52 6 7899 238 42613192
Haemorrhoids thrombosed 22.64 17.52 6 7899 270 42613160
Bone infarction 22.20 17.52 6 7899 291 42613139
Pseudopolyp 21.89 17.52 6 7899 307 42613123
Gastrointestinal tract irritation 21.38 17.52 6 7899 335 42613095
Restrictive cardiomyopathy 20.57 17.52 7 7898 743 42612687
Blood albumin abnormal 20.19 17.52 6 7899 411 42613019
Gastrointestinal scarring 19.79 17.52 5 7900 186 42613244
Intra-abdominal haemorrhage 19.68 17.52 10 7895 2918 42610512
Blood bilirubin increased 19.50 17.52 31 7874 42221 42571209
Toxic epidermal necrolysis 18.82 17.52 24 7881 26726 42586704
Starvation 18.70 17.52 6 7899 530 42612900
Postoperative delirium 18.04 17.52 6 7899 594 42612836

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 4198.15 15.24 2102 25840 451988 110109369
Hyperhidrosis 492.64 15.24 395 27547 186903 110374454
Temperature regulation disorder 463.68 15.24 159 27783 12667 110548690
Foetal death 439.94 15.24 162 27780 15883 110545474
Food allergy 426.61 15.24 168 27774 19780 110541577
Nightmare 386.28 15.24 191 27751 38672 110522685
International normalised ratio fluctuation 349.55 15.24 98 27844 3982 110557375
Upper respiratory tract infection 340.79 15.24 275 27667 131053 110430304
Immunodeficiency 330.86 15.24 172 27770 38666 110522691
Contrast media allergy 329.06 15.24 90 27852 3333 110558024
Psoriasis 317.18 15.24 271 27671 139722 110421635
Sedation 289.69 15.24 194 27748 69489 110491868
Serotonin syndrome 288.37 15.24 182 27760 58971 110502386
Bloody discharge 282.07 15.24 76 27866 2657 110558700
Coeliac disease 278.28 15.24 159 27783 43028 110518329
Drug intolerance 255.01 15.24 405 27537 406107 110155250
Nephrolithiasis 245.98 15.24 172 27770 66040 110495317
Lyme disease 239.28 15.24 74 27868 4242 110557115
Myoglobin urine present 213.47 15.24 49 27893 871 110560486
Rash erythematous 202.93 15.24 167 27775 81665 110479692
Prescribed overdose 193.03 15.24 167 27775 87414 110473943
Fluid retention 190.22 15.24 171 27771 94136 110467221
Obliterative bronchiolitis 157.63 15.24 52 27890 3671 110557686
Nausea 153.05 15.24 666 27276 1235024 109326333
Infusion related reaction 149.53 15.24 310 27632 380852 110180505
Treatment failure 142.56 15.24 253 27689 276981 110284376
Rheumatoid arthritis 142.12 15.24 264 27678 299349 110262008
Intentional product misuse 136.39 15.24 168 27774 132736 110428621
Bursitis 128.14 15.24 161 27781 129757 110431600
Hypertension 121.47 15.24 342 27600 509742 110051615
Exposure during pregnancy 118.97 15.24 177 27765 167247 110394110
Thrombocytopenia 118.73 15.24 268 27674 348617 110212740
Amylase increased 111.03 15.24 57 27885 12462 110548895
Overdose 110.78 15.24 206 27736 233588 110327769
Decreased immune responsiveness 103.73 15.24 50 27892 9556 110551801
Product used for unknown indication 89.50 15.24 29 27913 1934 110559423
Toxic encephalopathy 87.33 15.24 52 27890 15162 110546195
Back pain 84.54 15.24 245 27697 370751 110190606
Joint swelling 77.54 15.24 267 27675 442578 110118779
Drug ineffective 75.14 15.24 646 27296 1519894 109041463
Condition aggravated 70.40 15.24 50 27892 734786 109826571
Constipation 69.98 15.24 224 27718 357562 110203795
Erythema 68.80 15.24 195 27747 291252 110270105
Asthma 67.61 15.24 176 27766 250115 110311242
Contraindicated product administered 66.47 15.24 174 27768 248093 110313264
Infection 63.90 15.24 219 27723 361981 110199376
Vomiting 63.49 15.24 420 27522 910255 109651102
Rash 62.36 15.24 387 27555 820577 109740780
Iron deficiency 59.41 15.24 44 27898 18432 110542925
Herpes zoster 58.30 15.24 101 27841 108278 110453079
Troponin increased 58.05 15.24 53 27889 29713 110531644
Hypersensitivity 56.78 15.24 227 27715 403771 110157586
Product use issue 55.43 15.24 189 27753 311506 110249851
Blood potassium increased 54.91 15.24 54 27888 33195 110528162
General physical health deterioration 53.97 15.24 20 27922 425275 110136082
Pain 50.79 15.24 413 27529 954542 109606815
Secretion discharge 49.48 15.24 41 27901 20203 110541154
Retching 49.42 15.24 43 27899 22639 110538718
Platelet count increased 45.80 15.24 44 27898 26290 110535067
Bronchitis chronic 45.28 15.24 23 27919 4917 110556440
Pyrexia 43.76 15.24 381 27561 897884 109663473
Death 42.01 15.24 70 27872 698799 109862558
Alopecia 41.70 15.24 20 27922 364733 110196624
Blood lactate dehydrogenase increased 40.61 15.24 53 27889 44281 110517076
Respiratory arrest 40.45 15.24 61 27881 58238 110503119
Hepatic enzyme increased 40.11 15.24 174 27768 320718 110240639
Synovitis 39.96 15.24 10 27932 274082 110287275
Blister 37.94 15.24 6 27936 227370 110333987
Diarrhoea 37.25 15.24 155 27787 1139350 109422007
Hand deformity 35.94 15.24 6 27936 218500 110342857
Staphylococcal infection 33.53 15.24 62 27880 69882 110491475
Disease progression 33.52 15.24 10 27932 244024 110317333
Product dose omission issue 33.32 15.24 20 27922 321762 110239595
Weight increased 32.33 15.24 35 27907 419609 110141748
Stomatitis 32.15 15.24 14 27928 270228 110291129
Peripheral swelling 31.90 15.24 33 27909 404001 110157356
Lung disorder 31.80 15.24 4 27938 180043 110381314
Discomfort 30.97 15.24 8 27934 214699 110346658
Chills 30.77 15.24 112 27830 190468 110370889
Asthenia 30.51 15.24 82 27860 688917 109872440
Nasopharyngitis 30.25 15.24 33 27909 394328 110167029
Drug abuser 29.78 15.24 18 27924 5391 110555966
Wound 29.76 15.24 11 27931 234426 110326931
Wheezing 29.15 15.24 14 27928 255216 110306141
Neutropenia 29.12 15.24 31 27911 374589 110186768
Administration related reaction 28.96 15.24 8 27934 307 110561050
Urticaria 28.42 15.24 157 27785 318700 110242657
Pericarditis 28.29 15.24 10 27932 219104 110342253
Weight decreased 27.07 15.24 48 27894 468009 110093348
Hallucination 27.01 15.24 71 27871 101361 110459996
Dyspnoea 26.27 15.24 168 27774 1106704 109454653
Arthralgia 26.08 15.24 105 27837 779527 109781830
Anti-cyclic citrullinated peptide antibody positive 25.83 15.24 7 27935 181977 110379380
Acute kidney injury 25.65 15.24 79 27863 635351 109926006
Arthropathy 25.63 15.24 21 27921 287501 110273856
Sinusitis 24.84 15.24 23 27919 296665 110264692
Blood creatine phosphokinase increased 24.62 15.24 56 27886 73021 110488336
Impaired healing 23.70 15.24 10 27932 196707 110364650
Duodenal ulcer perforation 23.12 15.24 8 27934 177692 110383665
COVID-19 22.98 15.24 17 27925 245043 110316314
Mobility decreased 22.88 15.24 16 27926 237406 110323951
Decreased appetite 22.29 15.24 55 27887 475791 110085566
Psoriatic arthropathy 22.15 15.24 11 27931 196750 110364607
Systemic lupus erythematosus 22.15 15.24 19 27923 254319 110307038
Contusion 22.13 15.24 16 27926 233345 110328012
Oedema 21.80 15.24 13 27929 209963 110351394
Extremity contracture 21.57 15.24 10 27932 1751 110559606
Limb mass 21.31 15.24 13 27929 3956 110557401
Pemphigus 21.29 15.24 14 27928 214556 110346801
Liver disorder 21.10 15.24 5 27937 142238 110419119
C-reactive protein increased 20.58 15.24 15 27927 217904 110343453
Therapeutic product effect incomplete 20.46 15.24 111 27831 223694 110337663
Pneumonia 20.30 15.24 134 27808 876580 109684777
Neuropathy peripheral 20.21 15.24 10 27932 179267 110382090
Lower respiratory tract infection 20.16 15.24 19 27923 243087 110318270
Moaning 20.15 15.24 9 27933 1446 110559911
Injection site pain 19.95 15.24 10 27932 177912 110383445
Blood cholesterol increased 19.81 15.24 11 27931 184774 110376583
Respiratory alkalosis 19.24 15.24 14 27928 5707 110555650
Intentional product use issue 18.72 15.24 21 27921 247885 110313472
Interstitial lung disease 18.60 15.24 6 27936 139328 110422029
Cardiac aneurysm 18.59 15.24 9 27933 1736 110559621
Fall 18.48 15.24 84 27858 603398 109957959
C-reactive protein abnormal 18.38 15.24 5 27937 129690 110431667
Pancreatic carcinoma recurrent 17.85 15.24 5 27937 202 110561155
Muscular weakness 17.74 15.24 22 27920 248446 110312911
Ill-defined disorder 17.31 15.24 9 27933 156844 110404513
Dyspnoea exertional 16.79 15.24 3 27939 104057 110457300
Breath sounds absent 16.75 15.24 5 27937 254 110561103
Anaphylactic reaction 16.63 15.24 65 27877 114235 110447122
Restrictive cardiomyopathy 16.11 15.24 7 27935 1054 110560303
Therapeutic product effect decreased 16.05 15.24 23 27919 244293 110317064
Therapy non-responder 15.96 15.24 10 27932 157297 110404060
Abdominal discomfort 15.84 15.24 49 27893 393809 110167548
Type 2 diabetes mellitus 15.72 15.24 13 27929 177219 110384138
Gastrointestinal disorder 15.68 15.24 23 27919 241929 110319428
Anaemia 15.66 15.24 78 27864 547008 110014349
Blood creatinine increased 15.51 15.24 14 27928 182875 110378482
Osteoarthritis 15.46 15.24 14 27928 182609 110378748
Alanine aminotransferase increased 15.37 15.24 89 27853 183684 110377673

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02AB02 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Phenylpiperidine derivatives
ATC N02AB52 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Phenylpiperidine derivatives
ATC N02AB72 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Phenylpiperidine derivatives
ATC N02AG03 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Opioids in combination with antispasmodics
MeSH PA D000700 Analgesics
MeSH PA D000701 Analgesics, Opioid
MeSH PA D000759 Adjuvants, Anesthesia
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D009294 Narcotics
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35482 opioid analgesic
CHEBI has role CHEBI:53784 antispasmodic drug
CHEBI has role CHEBI:55322 μ-opioid receptor agonist
CHEBI has role CHEBI:59282 κ-opioid receptor agonist
FDA MoA N0000175684 Full Opioid Agonists
FDA EPC N0000175690 Opioid Agonist

Related Drugs by ATC class:

N02AB Phenylpiperidine derivatives 2 drugs
fentanylketobemidone
N02AG Opioids in combination with antispasmodics 3 drugs
hydromorphoneketobemidonemorphine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000
General anesthesia indication 50697003
Severe pain indication 76948002
Labor pain indication 247412007
Local anesthesia indication 386761002
Sedation as Adjunct to Anesthesia indication
Dependent drug abuse contraindication 6525002
Necrosis contraindication 6574001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Hyperbilirubinemia contraindication 14783006 DOID:2741
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Agranulocytosis contraindication 17182001 DOID:12987
Jaundice contraindication 18165001
Lowered convulsive threshold contraindication 19260006
Disorder of the central nervous system contraindication 23853001 DOID:331
Alcohol intoxication contraindication 25702006
Gangrene contraindication 36024000
Hypothyroidism contraindication 40930008 DOID:1459
Myxedema contraindication 43153006 DOID:11634
Low blood pressure contraindication 45007003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Thrombophlebitis contraindication 64156001 DOID:3875
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Poisoning by acetaminophen contraindication 70273001
Sleep apnea contraindication 73430006 DOID:0050847
Extrapyramidal disease contraindication 76349003
Urethral stricture contraindication 76618002
Decreased respiratory function contraindication 80954004
Disorder of brain contraindication 81308009 DOID:936
Injury of head contraindication 82271004
Chronic idiopathic constipation contraindication 82934008
Cor pulmonale contraindication 83291003 DOID:8515
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Gastrointestinal obstruction contraindication 126765001
Hb SS disease contraindication 127040003 DOID:10923
Seizure disorder contraindication 128613002
Drug-induced psychosis contraindication 191483003 DOID:1742
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Pheochromocytoma contraindication 302835009
Bone marrow depression contraindication 307762000
Coma contraindication 371632003
Primary adrenocortical insufficiency contraindication 373662000
Angle-closure glaucoma contraindication 392291006 DOID:13550
Breastfeeding (mother) contraindication 413712001
Central nervous system depression contraindication 418072004
Acute exacerbation of asthma contraindication 708038006
Injection Site Sequelae contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Mu-type opioid receptor GPCR AGONIST Ki 6.04 CHEMBL CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.49 CHEMBL
Sodium-dependent dopamine transporter Transporter WOMBAT-PK
Kappa-type opioid receptor GPCR Ki 5.63 WOMBAT-PK
Glutamate receptor ionotropic, NMDA 3A Ion channel WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 4.65 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.39 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 4.75 CHEMBL
Mu-type opioid receptor GPCR Ki 6.35 CHEMBL
Opioid receptor GPCR EC50 6.15 CHEMBL
Opioid receptor GPCR IC50 6.30 CHEMBL

External reference:

IDSource
4019813 VUID
N0000147902 NUI
D01383 KEGG_DRUG
50-13-5 SECONDARY_CAS_RN
4018030 VANDF
4019813 VANDF
C0025376 UMLSCUI
CHEBI:6754 CHEBI
CHEMBL607 ChEMBL_ID
DB00454 DRUGBANK_ID
CHEMBL1701 ChEMBL_ID
4058 PUBCHEM_CID
7221 IUPHAR_LIGAND_ID
103755 RXNORM
1858 MMSL
5046 MMSL
d00017 MMSL
001542 NDDF
004620 NDDF
2878005 SNOMEDCT_US
387298007 SNOMEDCT_US
54544005 SNOMEDCT_US
D008614 MESH_DESCRIPTOR_UI
411 INN_ID
9E338QE28F UNII
9E338QE28F INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-3545 SOLUTION 50 mg ORAL ANDA 32 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-3545 SOLUTION 50 mg ORAL ANDA 32 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-4595 TABLET 50 mg ORAL ANDA 32 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-4595 TABLET 50 mg ORAL ANDA 32 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-4596 TABLET 100 mg ORAL ANDA 32 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-4596 TABLET 100 mg ORAL ANDA 32 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-8595 TABLET 50 mg ORAL ANDA 32 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-8595 TABLET 50 mg ORAL ANDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1176 INJECTION, SOLUTION 25 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1176 INJECTION, SOLUTION 25 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1178 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1178 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1179 INJECTION, SOLUTION 75 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1179 INJECTION, SOLUTION 75 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1180 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1180 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1181 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1181 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1362 INJECTION, SOLUTION 25 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1362 INJECTION, SOLUTION 25 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1418 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 33 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1418 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 33 sections
MEPERIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0641-6052 INJECTION 25 mg INTRAMUSCULAR ANDA 31 sections
MEPERIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0641-6053 INJECTION 50 mg INTRAMUSCULAR ANDA 31 sections
MEPERIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0641-6054 INJECTION 100 mg INTRAMUSCULAR ANDA 31 sections
Demerol HUMAN PRESCRIPTION DRUG LABEL 1 30698-335 TABLET 50 mg ORAL NDA 34 sections
Demerol HUMAN PRESCRIPTION DRUG LABEL 1 30698-337 TABLET 100 mg ORAL NDA 34 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42806-050 TABLET 50 mg ORAL ANDA 30 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42806-051 TABLET 100 mg ORAL ANDA 30 sections
Meperidine HCl HUMAN PRESCRIPTION DRUG LABEL 1 52533-042 INJECTION, SOLUTION 10 mg INTRAVENOUS unapproved drug other 1 sections